Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
about
Small-Molecule Inhibitors of the Type III Secretion SystemVaccines for Pseudomonas aeruginosa: a long and winding roadChallenges and future in vaccines, drug development, and immunomodulatory therapyV-antigen homologs in pathogenic gram-negative bacteriaAssociation between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a reviewMutations in the Pseudomonas aeruginosa needle protein gene pscF confer resistance to phenoxyacetamide inhibitors of the type III secretion system.Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models.The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host responseSynthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS).Host-pathogen interplay in the respiratory environment of cystic fibrosis.Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide.Beyond Antibiotics: New Therapeutic Approaches for Bacterial Infections.New perspectives in the management of Pseudomonas aeruginosa infections.Approaches targeting the type III secretion system to treat or prevent bacterial infections.New and Emerging Treatments for Cystic Fibrosis.2014 year in review: Cystic fibrosis.Current and future therapies for Pseudomonas aeruginosa infection in patients with cystic fibrosis.Precision medicine for the treatment of severe pneumonia in intensive care.New drug developments in the management of cystic fibrosis lung disease.Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.Matrix exopolysaccharides; the sticky side of biofilm formation.The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults.Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.Antibody engineering and therapeutics, The Annual Meeting of the Antibody Society: December 8-12, 2013, Huntington Beach, CAThree-dimensional electron microscopy reconstruction and cysteine-mediated crosslinking provide a model of the type III secretion system needle tip complex.A multifunctional bispecific antibody against Pseudomonas aeruginosa as a potential therapeutic strategy.Pathoblockers or antivirulence drugs as a new option for the treatment of bacterial infectionsin Chronic Lung Infections: How to Adapt Within the Host?
P2860
Q26781403-71B8E013-B4BD-4F2D-A8E2-F051D25AA018Q26852817-2D85957B-1ABD-48E7-A2B8-3868EE5445C7Q26853354-DDC29074-7F1F-4E9E-863E-7FD8FA836903Q27008415-A59661E8-92F7-44A3-87CF-8789C3DCD03CQ27013824-6D3A712F-0B14-4A16-B59B-482545955B1BQ33622815-F9C4605B-654E-4806-AACE-66E90D9DF31AQ33822579-F4727EB4-2889-4BC4-9DD2-07A9CD0C45E3Q34711734-1AF22C63-CDA9-4A40-BC78-E951F89C18CFQ35118409-A3599F96-700E-4729-8B08-414377380B91Q35799736-D89E4477-C5BA-4659-BACC-E91448D75A6FQ36487854-4BFC6079-0EB5-45AC-BC7D-7570CAD9820CQ36991788-4A316F42-CD99-41AD-ACDC-389B0DA0C1A2Q38243221-5AAE6BD7-0FFD-4CBF-AC7D-D55F7CB57964Q38366322-701C5FE7-F820-48BE-9224-6DE363E5DAB1Q38532426-73F585BB-0509-4E5A-8FD0-965C23E56C43Q38582563-A9534F4A-A051-48B9-9261-68EC9666A452Q38635530-2F4451F6-C745-44F3-8631-AA82CAD45070Q38704065-F2D7AE37-1477-409F-9429-95EF0D4BF8FEQ38790382-51C3AA42-2619-4D84-978A-2987624D9BA7Q40093582-C5E5FB6A-CEE4-4985-A918-5704A54A7FCFQ40176201-1D37BD3C-D6A1-4AD9-A9C2-A1BDA9D8DFFDQ40601021-2F233AD7-6FFA-4F48-8C9D-9EB3A7C6D6B8Q40860257-BE07ABF1-65A8-4D55-92E8-F44B029E5367Q41380601-7C2AC1D3-E6EE-4D0E-A5D6-7F1994C20B99Q42557137-0041ADC7-9AF7-49E2-A241-F9294B351420Q42566246-40802242-709D-4FCC-852F-913B6C3FE277Q43083370-1628CD6F-D8D6-41DF-BAB8-89F25AEC7D35Q58571681-A7E8F500-098C-49A1-ABD8-E79A537D13C7Q58580408-6991108D-B68D-4A17-9E6A-5B5AB3A4B7D0
P2860
Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@ast
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@en
type
label
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@ast
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@en
prefLabel
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@ast
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@en
P2093
P2860
P356
P1476
Anti-PcrV antibody in cystic f ...... s aeruginosa airway infection.
@en
P2093
Carlos E Milla
David E Geller
Frank J Accurso
Geoffrey Yarranton
James F Chmiel
KB001 Study Group
Michael W Konstan
P2860
P304
P356
10.1002/PPUL.22890
P577
2013-09-09T00:00:00Z